

Franklin Biotechnology Discovery Fund

Class A (acc) EUR-H1 • ISIN LU1803069274 • A sub-fund of Franklin Templeton Investment Funds
The management company is Franklin Templeton International Services S.à r.l.

Objectives and Investment Policy

Franklin Biotechnology Discovery Fund (the “**Fund**”) investment objective is to seek long-term investment growth, through growth of capital.

Investment Policy

The Fund mainly invests in equities of biotechnology companies and discovery research firms of any market capitalisation. This may include companies involved with genomics, genetic engineering and gene therapy as well as companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals, and agriculture. These investments may be from anywhere in the world, although the Fund may invest significantly in the US.

To a lesser extent, the Fund may invest in corporate bonds, private companies, private investments in public equity (PIPEs) and special purpose acquisition companies (SPACs).

SFDR category Article 8 (promotes environmental and/or social characteristics under EU regulations).

The investment manager applies a proprietary rating methodology using various ESG criteria to assess long-term opportunities and risks. The Fund favours issuers with a high or improving profile and excludes or restricts investments in certain industries that are harmful to the environment or society, such as thermal coal, weapons and tobacco. The investment manager engages in dialogue with companies concerning ESG issues.

For more information see www.franklintempleton.lu/4912

Benchmark(s) NASDAQ Biotechnology Index. Used for performance comparison only.

The Fund is actively managed and may deviate materially from that of the benchmark(s).

Base currency US dollar (USD).

Buying and selling shares

You may normally buy or sell shares on any day the New York Stock Exchange is open for business.

Intended retail investor

Investors who understand the risks of the Fund and plan to invest for at least 5 years. The Fund may appeal to investors who:

- are looking for long-term investment growth
- are interested in a thematic exposure to global equity markets as part of a diversified portfolio
- have a high risk profile and can tolerate significant short-term changes in the share price

Product availability The Fund is available to all investors with at least basic investment knowledge, through a wide range of distribution channels, with or without the need for advice.


Terms to Understand

equities: Securities that represent partial ownership of a company.

Share Class Currency: EUR

Treatment of Income: The income received from the Fund's investments is accumulated with the result of increasing the value of the shares.

Risk and Reward Profile



What does this indicator mean and what are its limits?

This indicator is designed to provide you with a measure of the price movement of this share class based on historical behavior.

Historical data may not be a reliable indication of the future risk profile of the Fund. The category shown is not guaranteed to remain unchanged and may shift over time.

The lowest category does not mean risk free.

As the share class has no sufficient historical data available, simulated data based on a representative portfolio model or benchmark have been used instead.

Why is the Fund in this specific category?

The Fund invests mainly in equity securities of biotechnology companies. Such securities have historically been subject to significant price movements that may occur suddenly due to market, sector or company-specific factors. As a result, the performance of the Fund can fluctuate significantly over relatively short time periods.

Risks materially relevant not adequately captured by the indicator:

Liquidity risk: the risk that arises when adverse market conditions affect the ability to sell assets when necessary. Such risk may be triggered by (but not limited to) unexpected events such as environmental disasters or pandemics. Reduced liquidity may have a negative impact on the price of the assets.

Equity risk: prices of equities may be affected by factors such as economic, political, market, and issuer-specific changes. Such changes may adversely affect the value of the equities regardless of company-specific performance.

Securities Lending risk: the risk that default or insolvency of the borrower of securities lent by a Fund may lead to losses if collateral received realises less than the values of securities lent.

For a full discussion of all the risks applicable to this Fund, please refer to the “Risk Considerations” section of the current prospectus of Franklin Templeton Investment Funds.

Charges

The charges you pay are used to pay the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

One-off charges taken before or after you invest

Entry charge	5.75%
Exit charge	Not applicable

This is the maximum that might be taken out of your money before it is invested.

Charges taken from the Fund over a year

Ongoing charges	1.79%
------------------------	-------

Charges taken from the Fund under certain specific conditions


Performance fee	Not applicable
------------------------	----------------

The entry charges shown are maximum amounts; you may pay less in some cases. For more information, please see your financial adviser.

The ongoing charges are based on the expenses for the year ending 31 December 2024. This figure may vary from year to year.

For detailed information about charges, please refer to the sections “Share Classes” and/or “Performance Fees” (as applicable) as well as Appendix E of the current prospectus of Franklin Templeton Investment Funds.

Past Performance



A: The performance was achieved under circumstances that no longer apply.
 (Benchmark performance is provided for information and indicative purposes only.)

- The past performance up to the launch date of the share class has been simulated by taking the performance of another existing share class of the Fund, which does not differ materially in the extent of its participation in the assets of the Fund.
- Past performance is not a guide to future performance.
- The past performance shown here includes all the ongoing charges but not the entry charge.
- The Fund was launched in 2000 and the present share class on 04/06/2018.
- Past performance is calculated in the currency of the present share class.
- Product performance is not tracking the index.

Practical Information

- The Custodian of Franklin Templeton Investment Funds is J.P. Morgan SE, Luxembourg Branch.
- Copies of the latest prospectus and the latest annual and semi-annual reports of Franklin Templeton Investment Funds are available in the language of this document, on the website www.ftdocuments.com or may be obtained free of charge from Franklin Templeton International Services S.à r.l., 8A, rue Albert Borschette, L-1246 Luxembourg or your financial adviser.
- The latest prices and other information on the Fund (including other share classes of the Fund) are available from Franklin Templeton International Services S.à r.l., 8A, rue Albert Borschette, L-1246 Luxembourg, www.fundinfo.com or www.franklintempleton.lu.
- Please note that the taxation regime applicable in the Grand Duchy of Luxembourg may have an impact on your personal tax position. Please consult your financial or tax adviser before deciding to invest.
- Franklin Templeton International Services S.à r.l. may be held liable solely on the basis of any statement contained in this document that is

misleading, inaccurate or inconsistent with the relevant parts of the prospectus of the Fund.

- The present Fund is a sub-fund of Franklin Templeton Investment Funds. The prospectus and the financial reports refer to all sub-funds of Franklin Templeton Investment Funds. All sub-funds of Franklin Templeton Investment Funds have segregated assets and liabilities. As a result, each sub-fund is operated independently from each other.
- You may switch into shares of another sub-fund of Franklin Templeton Investment Funds as further described in the prospectus.
- The details of the up-to-date remuneration policy, including, but not limited to, a description of how remuneration and benefits are calculated, the identity of persons responsible for awarding the remuneration and benefits including the composition of the remuneration committee are available at www.franklintempleton.lu and a paper copy can be obtained free of charge.